Dr Philip Arlen | President and Chief Executive Officer
Precision Biologics Inc

Dr Philip Arlen, President and Chief Executive Officer, Precision Biologics Inc

Dr. Arlen is the  President, CEO and Chief Medical Officer of Precision Biologics. Prior to joining Precision Biologics, Inc., he served as President, CEO, and Chief Medical Officer at Neogenix Oncology, Inc. Dr. Arlen spent 11 years at the National Cancer Institute, USA, most recently as the Director of the Clinical Research Group for the Laboratory of Tumor Immunology and Oncology. At the NCI, Dr. Arlen focused on the development of a programmatic approach to vaccine clinical trials conducted at the NCI as well as at numerous other Cancer Centers throughout the U.S. During his tenure at the NCI, Dr. Arlen was the Principal Investigator and/or Associate Investigator on numerous clinical trials involving the use of cancer vaccines and other immunostimulatory molecules.
Dr. Arlen remains on the clinical staff at both the NCI Clinical Center as well as the Walter Reed National Military Medical Center. He has authored or co-authored over 100 peer reviewed manuscripts in internationally known scientific and medical journals. Dr. Arlen received an NIH Award of Merit for major contributions to the field of cancer immunotherapy in 2003. He is a board certified medical oncologist and received his BA from Emory University and his MD from Medical College of Georgia, School of Medicine

Appearances:



Day 3 Oct 12th Immune Profiling @ 13:50

Targeting cancer neoantigens: a promising source of immunogens for cancer immunotherapy

 
  • Employing novel antibodies against immunogenic neoantigens
  • Antibody development using a novel platform exploiting immunogenic human tumor antigens
  • How to identify tumor specific monoclonal antibodies with anti-tumor activity and target antigens
  • Sharing pre-clinical and PhII clinical data in patients  

back to speakers